Stem cell transplantation

Hematopoietic stem cell transplantation (HSCT) or bone marrow transplantation is a medical procedure in the field of hematology and oncology that involves transplantation of hematopoietic stem cells (HSC). It is most often performed for people with diseases of the blood or bone marrow, or certain types of cancer.

Bone marrow transplantation was pioneered at the Fred Hutchinson Cancer Research Center from the 1950s through the 1970s by E. Donnall Thomas, whose work was later recognized with a Nobel Prize in Physiology and Medicine. Dr. Thomas' work showed that bone marrow cells infused intravenously could repopulate the bone marrow and produce new blood cells. His work also reduced the likelihood of developing a life-threatening complication called Graft-versus-host disease. However it remains a risky procedure and it is reserved for patients with life threatening diseases.

The first physician to perform a successful human bone marrow transplant was Robert A. Good.

Principles

Most recipients of HSCTs are leukemia patients or others who would benefit from treatment with high doses of chemotherapy or total body irradiation. Other patients who receive bone marrow transplants include pediatric cases where the patient has an inborn defect such as severe combined immunodeficiency or congenital neutropenia and was born with defective stem cells. Children or adults with aplastic anemia have lost their stem cells after birth and may not require such high doses of chemotherapy and irradiation prior to a transplant. In this case there is a greater need for immunosuppressive agents. Other conditions that bone marrow transplants are considered for include thalassemia major, sickle-cell disease, myelodysplastic syndrome, lymphoma, Hodgkin's disease, and multiple myeloma. More recently non-myeloablative, or so-called "mini transplant", procedures have been developed which do not require such large doses of chemotherapy and radiation. This has allowed HSCT to be conducted in older patients and without the need for hospitalization.

tem cell collection

Types of donors

There are two major types of bone marrow transplantation. "Autologous" bone marrow transplantation involves isolation of HSC from a patient, storage of the stem cells in a freezer, medical treatment of the patient that destroys stem cells remaining in the body, and return of the patient's own stored stem cells to their body. Autologous transplants have the advantage of a lower risk of graft rejection, infection and graft-versus-host disease. "Allogeneic" bone marrow transplantation involves two people, one is the (normal) donor and one is the (patient) recipient. Allogeneic HSC donors must have a tissue (HLA) type that matches the recipient and, in addition, the recipient requires immunosuppressive medications. Allogeneic transplant donors may be related (usually a sibling) or unrelated volunteers.

Donor selection

A major limitation of allogeneic bone marrow transplantation is a shortage of donors. To avoid rejection of the transplanted stem cells or severe graft-versus-host disease, the donor should have the same human leukocyte antigens (HLA) as the recipient. About 25 to 30 percent of potential HSCT recipients have an HLA-identical sibling. For other recipients, registries of volunteer unrelated donors can be quickly searched in order to find a potential HLA match. If an exact match cannot be found, a partially matched donor can be used. However, the use of mismatched donors may increase the risk of graft rejection or severe graft-versus-host disease.

A compatible donor is found by doing additional HLA-testing from the blood of potential donors. The HLA genes fall in two categories (Type I and Type II). In general, mismatches of the Type-I genes (i.e. HLA-A, HLA-B, or HLA-C) increase the risk of graft rejection. A mismatch of an HLA Type II gene (i.e. HLA-DR, or HLA-DQB1) increases the risk of graft-versus-host disease. In addition a genetic mismatch as small as a single DNA base pair is significant so perfect matches require knowledge of the exact DNA sequence of these genes for both donor and recipient. Leading transplant centers currently perform testing for all five of these HLA genes before declaring that a donor and recipient are HLA-identical.

Race and ethnicity are known to play a major role in donor recruitment drives, as members of the same ethnic group are more likely to have matching genes, including the genes for HLA. [http://www.marrow.org/DONOR/ABCs/index.html]

ources of HSC

In the case of a bone marrow transplant, the HSC are removed from a large bone of the donor, typically the pelvis, through a large needle that reaches the center of the bone. The technique is referred to as a bone marrow harvest and is performed under general anesthesia.

Peripheral blood stem cells are now the most common source of stem cells for HSCT. They are collected from the blood through a process known as apheresis. The donor's blood is withdrawn through a sterile needle in one arm and passed through a machine that removes white blood cells. The red blood cells are returned to the donor. The peripheral stem cell yield is boosted with daily subcutaneous injections of Granulocyte-colony stimulating factor.

Umbilical cord blood is obtained when a mother donates her infant's umbilical cord and placenta after birth. Cord blood has a higher concentration of HSC than is normally found in adult blood. However, the small quantity of blood obtained from an umbilical cord (typically about 50 mL) makes it more suitable for transplantation into small children than into adults. Newer techniques using ex-vivo expansion of cord blood units or the use of two cord blood units from different donors are being explored to allow cord blood transplants to be used in adults.

torage of HSC

Unlike other organs, bone marrow cells can be frozen for prolonged time periods (cryopreserved) without damaging too many cells. This is necessary for autologous HSC because the cells must be harvested months in advance of the transplant treatment. In the case of allogeneic transplants fresh HSC are preferred in order to avoid cell loss that might occur during the freezing and thawing process. Allogeneic cord blood is stored frozen at a cord blood bank because it is only obtainable at the time of childbirth. To cryopreserve HSC a preservative, DMSO, must be added and the cells must be cooled very slowly in a control rate freezer to prevent osmotic cellular injury during ice crystal formation. HSC may be stored for years in a "cryofreezer" which typically utilizes liquid nitrogen because it is non-toxic and it is very cold (boiling point -196°C.)

Conditioning regimens

The chemotherapy or irradiation given immediately prior to a transplant is called the conditioning or preparative regimen. The purpose is to help eradicate the patient's disease prior to the infusion of HSC and to suppress immune reactions. Chemotherapy drugs and radiation both damage DNA in the cell nucleus which kills rapidly dividing cells by triggering a self-destruct mechanism called apoptosis. Bone marrow cells divide frequently and are particularly sensitive to this treatment. The bone marrow can be "ablated" at doses that cause minimal injury to other tissues. In allogeneic transplants, a combination of cyclophosphamide with busulfan or total body irradiation is commonly employed. This treatment also has immunosuppressive effect which prevents rejection of the HSC by the recipients immune system. Autologous transplants may also use these conditioning regimens but many other chemotherapy combinations can be used depending on the type of disease.

Non-myeloablative allogeneic HSCT is a newer treatment approach which uses lower doses of chemotherapy and radiation which are too low to eradicate all of the bone marrow cells of a recipient. Instead non-myeloablative transplants rely on the "graft versus tumor" effect for their benefit. They do require high doses of immunosuppressive agents in the early stages of treatment. This leads to a state of mixed chimerism early after transplant where both recipient and donor HSC coexist in the bone marrow space. Decreasing doses of immunosuppressive therapy then allows donor T-cells to eradicate the remaining recipient HSC and to induce graft-versus-host disease and the graft versus tumor effect.

Non-myeloablative (or "mini") allogeneic transplants, because of their gentler conditioning regimens, are associated with a lower risk of transplant-related mortality and therefore allow patients who are considered too high-risk for conventional allogeneic HSCT (because of age or other comorbidities) to undergo potentially curative therapy for their disease.

Transplantation and engraftment

HSC are infused into the blood stream of the recipient through an intravenous (i.v.) catheter, like any other i.v. fluid. The HSC briefly circulate in the blood stream and then into the bone marrow spaces where they grow and start to produce blood cells. After several weeks of growth in the bone marrow, expansion of HSC and their progeny is sufficient to normalize the blood cell counts and alleviate the need for red blood cell and platelet transfusions.

ide effects and complications

Bone marrow transplantation is associated with a fairly high mortality (10% or higher), which limits its use to conditions that are themselves essentially life-threatening. Major causes of complications are sepsis, graft-versus-host disease and veno-occlusive disease.

Regimen-related toxicity

"Regimen-related toxicities" are side-effects of the high dose chemotherapy or irradiation used in ablative HSCT.

Severe liver injury is termed hepatic veno-occlusive disease (VOD). Elevated levels of bilirubin, hepatomegaly and fluid retention are clinical hallmarks of this condition. Initially thought to be a specific form of Budd-Chiari syndrome (i.e. thrombosis of the liver veins). There is now a greater appreciation of the generalized cellular injury and obstruction in hepatic vein sinuses, and it has thus been referred to as sinusoidal obstruction syndrome (SOS). Severe case are associated with a high mortality. Anticoagulants or defibrotide may be effective in reducing the severity of VOD but may also increase bleeding complications. Ursodiol has been shown to help prevent VOD, presumably by helping the flow of bile.

"Mucositis" is the injury of the mucosal lining of the mouth and throat and is a common regimen-related toxicity following ablative HSCT regimens. It is usually not life-threatening but is very painful, and prevents eating and drinking. Mucositis is treated with pain medications plus intravenous infusions to prevent dehydration and malnutrition.

"Total Body Irradiation (TBI)" -related side effects are both acute (during treatment or shortly thereafter) and long-term (months to years later). Acute side effects include the risk of parotid gland swelling, headaches, nausea, vomiting, and hair-loss. Long-term side effects include >50% chance of developing cataracts, and a low but potentially dangerous risk of liver failure, kidney failure, and severe lung inflammation (pulmonary fibrosis).

Infection

Bone marrow transplantation usually requires that the recipient's own bone marrow is destroyed ("myeloablation"). Prior to "engraftment" patients may go for several weeks without appreciable numbers of white blood cells to help fight infection. This puts a patient at risk of infections, sepsis and septic shock despite prophylactic antibiotics. The immunosuppressive agents employed in allogeneic transplants for the prevention or treatment of graft-versus-host disease further increase the risk of opportunistic infection. Immunosuppressive drugs are given for a minimum of 6 months after a transplantation, or much longer if required for the treatment of graft-versus-host disease. Transplant patients lose their acquired immunity, for example immunity to childhood diseases such as measles or polio. For this reason transplant patients must be re-vaccinated with childhood vaccines once they are off of immunosuppressive medications.

Graft versus host

Graft-versus-host disease (GVHD)

Graft-versus-host disease is an inflammatory disease that is unique to allogeneic transplantation. It is an attack of the "new" bone marrow's immune cells against the recipient's tissues. This can occur even if the donor and recipient are HLA-identical because the immune system can still recognize other differences between their tissues. It is aptly named graft-versus-host disease because bone marrow transplantation is the only transplant procedure in which the transplanted cells must accept the body rather than the body accepting the new cells. "Acute graft-versus-host disease" typically occurs in the first three months after transplantation and may involve the skin, intestine, or the liver. Corticosteroids such as prednisone are a standard treatment. "Chronic graft-versus-host disease" may also develop after allogeneic transplant and is the major source of late complications. In addition to inflammation, chronic graft-versus-host disease may lead to the development of fibrosis, or scar tissue, similar to scleroderma or other autoimmune diseases and may cause functional disability, and the need for prolonged immunosuppressive therapy.

Graft versus tumor effect

The beneficial aspect of Graft versus Host is known as "graft versus tumor" or "graft versus leukemia". For example, leukemia patients with chronic graft-versus-host disease after an allogeneic transplant have a lower risk of leukemia relapse. This is due to a therapeutic immune reaction of the grafted donor lymphocytes against the diseased bone marrow of the recipient. This lower rate of relapse accounts for the increased success rate of allogeneic transplants compared to transplants from identical twins, and indicates that allogeneic HSCT is a form of immunotherapy. Graft vs tumor is also the major mechanism of benefit of non-myeloablative transplants which do not employ high dose chemotherapy or radiation.

If the body rejects the organ, the host has a strong risk of dying.

Conditions treated with bone marrow or HSC transplantation

Acquired

* Acute lymphocytic leukemia
* Acute myelogenous leukemia
* Aplastic anemia
* Chronic myelogenous leukemia (accelerated phase or blast crisis)
* Hodgkin's disease
* Multiple myeloma
* Myelodysplasia
* Non-Hodgkin's lymphoma
* Paroxysmal nocturnal hemoglobinuria (PNH; severe aplasia)
* Radiation poisoning
* Kahler's disease
* chronic lymphocytic leukemia
* AL amyloidosis

Congenital

* Adrenoleukodystrophy
* Amegakaryocytic Thrombocytopenia (CAMT)
* Griscelli syndrome type II
* Hurler syndrome
* Kostmann syndrome
* Krabbe disease
* Metachromatic leukodystrophy
* Thalassemia
* Hemophagocytic lymphohistiocytosis (HLH)
* Wiskott-Aldrich syndrome
* Some inborn errors of metabolism

References

*Thomas ED, Lochte HL, Lu WC et al. Intravenous infusion of bone marrow in patients receiving radiation and chemotherapy. "N Engl J Med" 1957; 157: 491-496. PMID 13464965. [http://scholar.google.com/scholar?cluster=2798804175407779630 Google Scholar]
*cite journal | author=Socié, Gérard, et al. | title=Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies | journal=Blood | month=December | year=2001 | volume=98(13) | pages=3569–3574 [http://www.bloodjournal.org/cgi/content/full/98/13/3569 Fulltext] . PMID 11739158.
*cite journal | author=Richardson PG, et al. | title=Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome | journal=Blood | month=December | year=2002 | volume=100(13) | pages=4337–43 PMID 12393437
*cite journal | author=Guglielmi, PT, et al. | title=Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma | journal=New England Journal of Medicine | month=December | year=1995 | volume=333(23) | pages=1540–5 PMID 7477169.
*cite journal | author=Barker JN, et al. | title=Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy | journal=Blood | month=December | year=2005 | volume=105(3) | pages=1343–1347 [http://www.bloodjournal.org/cgi/content/full/105/3/1343 Fulltext] . PMID 15466923.

External links

Marrow donor registries

* [http://www.abmdr.org.au/ Australian Bone Marrow Donor Registry]
* [http://www.bmdw.org/ Bone Marrow Donors Worldwide]
*U.S. National Marrow Donor Program
* [http://www.europdonor.nl/ Europdonor Foundation]
* [http://www.zkrd.de/ ZKRD German Bone Marrow Donor Registry]
* [http://www.blood.co.uk/pages/marrow_info.html The British Bone Marrow Registry]
* [http://www.giftoflife.org/ The Gift of Life Bone Marrow Foundation]
* [http://ibmdr.galliera.it/ Italian Bone Marrow Donor Registry]
* [http://www.dodmarrow.org/ C.W. Bill Young Department of Defense Marrow Donor Program]
* [http://www.ebmt.org/ European Group for Blood and Marrow Transplantation]
* [http://www.kmdp.or.kr/ Korea Marrow Donor Program]
* [http://www.anthonynolan.org.uk The Anthony Nolan Trust]

Bone marrow recruitment groups

* [http://www.aadp.org/ Asian American Donor Program]
* [http://www.asianmarrow.org/ Asians for Miracle Marrow Matches]
* [http://www.becauseicare.info/ Because I Care]
* [http://www.cllf.org/ Cammy Lee Leukemia Foundation]
* [http://www.mdpill.com/ International Bone Marrow Transplant Association]
* [http://www.icla.org/ Icla da Silva Foundation, Inc.]
* [http://www.kidsbeatingcancer.com/ Kids Beating Cancer, Inc.]
* [http://www.samarinfo.org/ South Asian Marrow Association of Recruiters]

Patient education

* [http://www.bonemarrow.org/ The Bone Marrow Foundation]
* [http://www.merck.com/mrkshared/mmanual/section12/chapter149/149h.jsp The Merck Manual of Diagnosis and Therapy] bone marrow transplantation page.
* [http://www.ncbi.nlm.nih.gov:80/books/bv.fcgi?rid=cmed.chapter.15785 Cancer Medicine] online textbook.
* [http://www.cancer.gov/cancertopics/factsheet/Therapy/bone-marrow-transplant Bone Marrow Transplantation and Peripheral Blood Stem Cell Transplantation: Questions and Answers] . National Cancer Institute.
* [http://www.bmtnews.org/ Blood & Marrow Transplant Information Network]
* [http://www.anthonynolan.org.uk/ Anthony Nolan Trust]
* [http://oncology.wustl.edu/ Bone Marrow Transplant and Medical Oncology at Washington University]
* [http://www.umgcc.org/patient_info/ask_the_expert.html University of Maryland Greenbaum Cancer Center Info]

Donor experience

* [http://www.marrowdonor.net Donating Bone Marrow: A detailed experience of donating marrow using traditional harvest]
* [http://www.blortland.com/MikesMarrowStory.html Mike's Marrow Donor Story]
* [http://www.fastbobs.com/bob/donor.html Bob's Donations]
* [http://www.redlefsen.com/redlefsen/Lorenzs_PBSC_Donations/Lorenzs_PBSC_Donations.html Lorenz's Donations]
* [http://www.transweb.org/people/live_don/experien/wdmyr_ls.htm The Right Thing to Do]
* [http://www.oncolink.org/coping/article.cfm?c=6&s=31&ss=76&id=105 My Personal Experience as a Bone Marrow Donor]
* [http://spanky.thehawkeye.com/features/1998/bonemarrow/index.html A Gift of Life]
* [http://www.bbc.co.uk/dna/h2g2/A197192 My Experience as a Bone Marrow Donor]
* [http://www.krisandsusanna.com/Writing/Marrow/Marrow_journal.htm Bone Marrow Donation: A Donor's Journal]
* [http://members.aol.com/marowdonor/index.html My Marrow Donation Experiences]

Transplantation and immunology

* [http://edumed.unige.ch/apprentissage/immunologie/ Website of Geneva University about transplantation immunology]

Organ transplantation